{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:04:29Z","timestamp":1790795069980,"version":"4.1.0"},"reference-count":36,"publisher":"Tottori University Faculty of Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Yonago Acta Med."],"published-print":{"date-parts":[[2020]]},"DOI":"10.33160\/yam.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T18:04:15Z","timestamp":1596737055000},"page":"188-197","source":"Crossref","is-referenced-by-count":24,"title":["Pemafibrate Dramatically Ameliorated the Values of Liver Function Tests and Fibrosis Marker in Patients with Non-Alcoholic Fatty Liver Disease"],"prefix":"10.33160","volume":"63","author":[{"given":"Suguru","family":"Ikeda","sequence":"first","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukako","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takakazu","family":"Nagahara","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Okano","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonoko","family":"Kitao","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhei","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Cardiovascular Medicine and Endocrinology and Metabolism, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[{"name":"Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18656","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-57. PMID:28714183, DOI:10.1002\/hep.29367","DOI":"10.1002\/hep.29367"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol. 2012;27:1555-60. PMID:22741595, DOI:10.1111\/j.1440-1746.2012.07222.x","DOI":"10.1111\/j.1440-1746.2012.07222.x"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol. 2018;53:362-76. PMID:29247356, DOI:10.1007\/s00535-017-1415-1","DOI":"10.1007\/s00535-017-1415-1"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-35. PMID:11818483, DOI:10.1146\/annurev.med.53.082901.104018","DOI":"10.1146\/annurev.med.53.082901.104018"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645-50. PMID:2129546, DOI:10.1038\/347645a0","DOI":"10.1038\/347645a0"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Abdelmegeed MA, Moon KH, Hardwick JP, Gonzalez FJ, Song BJ. Role of peroxisome proliferator-activated receptor-\u03b1 in fasting-mediated oxidative stress. Free Radic Biol Med. 2009;47:767-78. PMID:19539749, DOI:10.1016\/j.freeradbiomed.2009.06.017","DOI":"10.1016\/j.freeradbiomed.2009.06.017"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, et al. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-\u03b1 activator fenofibrate. J Biol Chem. 2004;279:16154-60. PMID:14764586, DOI:10.1074\/jbc.M400346200","DOI":"10.1074\/jbc.M400346200"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720-33. PMID:25450203, DOI:10.1016\/j.jhep.2014.10.039","DOI":"10.1016\/j.jhep.2014.10.039"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, et al.; K-877-04 Study Group. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36-43. PMID:27062408, DOI:10.1016\/j.atherosclerosis.2016.02.029","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, et al. Effects of pemafibrate, a novel selective PPARa modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: A randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41:538-46. PMID:29298800, DOI:10.2337\/dc17-1589","DOI":"10.2337\/dc17-1589"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Yamashita S, Masuda D, Matsuzawa Y. Pemafibrate, a new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep. 2020;22:5. PMID:31974794, DOI:10.1007\/s11883-020-0823-5","DOI":"10.1007\/s11883-020-0823-5"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K, et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep. 2017;7:42477. PMID:28195199, DOI:10.1038\/srep42477","DOI":"10.1038\/srep42477"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1964.tb00549.x"},{"key":"14","unstructured":"14. Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS. A review on laboratory liver function tests. Pan Afr Med J. 2009;3:17."},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Schwabe RF, Tabas I, Pajvani UB. Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. Gastroenterology. 2020;158:1913-28. PMID:32044315, DOI:10.1053\/j.gastro.2019.11.311","DOI":"10.1053\/j.gastro.2019.11.311"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Lazo-del Vallin S, et al. Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH. Liver Int. 2017;37:1887-96. PMID:28544769, DOI:10.1111\/liv.13480","DOI":"10.1111\/liv.13480"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2:e1912565. PMID:31584681, DOI:10.1001\/jamanetworkopen.2019.12565","DOI":"10.1001\/jamanetworkopen.2019.12565"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Irie M, Sohda T, Anan A, Fukunaga A, Takata K, Tanaka T. Reduced Glutathione suppresses Oxidative Stress in Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol. 2016;6:13-8. PMID:29201718, DOI:10.5005\/jp-journals-10018-1159","DOI":"10.5005\/jp-journals-10018-1159"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116-41. PMID:32156524, DOI:10.1016\/j.freeradbiomed.2020.02.025","DOI":"10.1016\/j.freeradbiomed.2020.02.025"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018;10:530-42. PMID:30190781, DOI:10.4254\/wjh.v10.i8.530","DOI":"10.4254\/wjh.v10.i8.530"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46:32-6. PMID:17567829, DOI:10.1002\/hep.21669","DOI":"10.1002\/hep.21669"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59:1265-9. PMID:20801772, DOI:10.1136\/gut.2010.216077","DOI":"10.1136\/gut.2010.216077"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104-12. PMID:19523535, DOI:10.1016\/j.cgh.2009.05.033","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26. PMID:12883497, DOI:10.1053\/jhep.2003.50346","DOI":"10.1053\/jhep.2003.50346"},{"key":"25","unstructured":"25. Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van Rensburg C, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH. S Afr Med J. 2011;101:477-80."},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Fern\u00e1ndez-Miranda C, P\u00e9rez-Carreras M, Colina F, L\u00f3pez-Alonso G, Vargas C, Sol\u00eds-Herruzo JA. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2008;40:200-5. PMID:18261709, DOI:10.1016\/j.dld.2007.10.002","DOI":"10.1016\/j.dld.2007.10.002"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Gandhi N, Lenton R, Bhartia M, Abbas A, Raju J, Ramachandran S. Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus. 2014;3:14. PMID:24455467, DOI:10.1186\/2193-1801-3-14","DOI":"10.1186\/2193-1801-3-14"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Yamashita S, Masuda D, Matsuzawa Y. Clinical applications of a novel selective PPAR\u03b1 modulator, pemafibrate, in dyslipidemia and metabolic diseases. J Atheroscler Thromb. 2019;26:389-402. PMID:30930344, DOI:10.5551\/jat.48918","DOI":"10.5551\/jat.48918"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Polyzos S, Slavakis A, Koumerkeridis G, Katsinelos P, Kountouras J. Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort. Horm Metab Res. 2019;51:134-40. PMID:30273934, DOI:10.1055\/a-0713-1330","DOI":"10.1055\/a-0713-1330"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Luyendyk J, Lisman T. Platelets as Modulators of Liver Diseases. Semin Thromb Hemost. 2018;44:114-25. PMID:28898899, DOI:10.1055\/s-0037-1604091","DOI":"10.1055\/s-0037-1604091"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Diggs LP, Greten TF. The effects of platelet accumulation in fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:393-4. PMID:31114057, DOI:10.1038\/s41575-019-0160-8","DOI":"10.1038\/s41575-019-0160-8"},{"key":"32","unstructured":"32. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50."},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Kurokawa T, Ohkohchi N. Platelets in liver disease, cancer and regeneration. World J Gastroenterol. 2017;23:3228-39. PMID:28566882, DOI:10.3748\/wjg.v23.i18.3228","DOI":"10.3748\/wjg.v23.i18.3228"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Wang L, Wang B, You H, Wu X, Zhou J, Ou X, et al. Platelets\u2019 increase is associated with improvement of liver fibrosis in entecavir-treated chronic hepatitis B patients with significant liver fibrosis. Hepatol Int. 2018;12:237-43. PMID:29700765, DOI:10.1007\/s12072-018-9864-z","DOI":"10.1007\/s12072-018-9864-z"},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64. PMID:24648894, DOI:10.3892\/br.2012.18","DOI":"10.3892\/br.2012.18"},{"key":"36","doi-asserted-by":"publisher","unstructured":"36. Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213-23. PMID:30708071, DOI:10.1016\/j.diabet.2019.01.008","DOI":"10.1016\/j.diabet.2019.01.008"}],"container-title":["Yonago Acta Medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/63\/3\/63_2020.08.009\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T23:46:45Z","timestamp":1598053605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yam\/63\/3\/63_2020.08.009\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.33160\/yam.2020.08.009","relation":{},"ISSN":["1346-8049"],"issn-type":[{"value":"1346-8049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}